1

Prescription Drug Affordability Review Board

Colorado Prescription Drug Affordability Review Board & Advisory Council

#FFFFFF

Colorado’s Prescription Drug Affordability Board (PDAB), established under Senate Bill 21-175, is a Type-1 Board within the Division of Insurance that will have the authority to review prescription drug costs and evaluate their impact on Coloradans. The Board may then recommend ways to address those costs and may set an upper payment limit for certain drugs. The Board has appointed a multi-stakeholder Advisory Council to provide input to the Board to ensure its work is informed by a variety of stakeholders.

#FFFFFF

Open PDAAC Position

The Prescription Drug Affordability Advisory Council (PDAAC) is seeking a new member to fill the role of health care consumer. If you are interested in joining the PDAAC, please fill out the following application. 

PDAAC Application

PDAB Listserv

​To receive PDAB and PDAAC updates directly in your inbox, click the button below. To subscribe, you will need to enter your email and then choose Updates From Divisions > Division of Insurance > Division of Insurance Prescription Drug Affordability Board.

Sign up for Division Notifications

PDAB Rulemaking Process

Each rule will appear throughout 3 separate PDAB meetings and there will be ample opportunity for stakeholder feedback. Stakeholders are encouraged to engage with DOI Board staff early and often during the rulemaking process. 

Meetings & Meeting Materials

PDAB Meetings & Materials

The Prescription Drug Affordability Board, in accordance with statute, will hold regular meetings every six weeks. All meetings are open to the public except portions of the meeting in which confidential information may be discussed. Board meetings will now be held on the Zoom platform.  

Next PDAB meeting & Rulemaking Hearing: Friday, October 7 from 10 am - 1 pm MT    
Register for PDAB Meeting

PDAB Meeting Materials

PDAAC Meetings & Materials

The Prescription Drug Affordability Advisory Council (PDAAC), in accordance with statute, will hold meetings quarterly. Advisory Council meetings will now be held on the Zoom platform. There will be opportunity for public comment at PDAAC meetings. The PDAAC will also hold two ad hoc meetings to discuss the draft proposed rules for Affordability Review and Upper Payment Limit Methodology.  

    PDAAC Meeting: Draft UPL Rule: Thursday, November 17 from 9 am - 12 pm MT    
Register for PDAAC Meeting 

PDAAC Meeting Materials

Meeting Recordings

2022 Meeting Recordings

 

 

#FFFFFF

Rulemaking Timelines

Updated Proposed Rulemaking Timeline & Suggested Written Testimony Deadlines
To allow for more time for stakeholders to respond to suggested changes to the Proposed Rule Part 3 - Affordability Review, Board staff are recommending the Board hold an additional rulemaking hearing (allowing for a 3rd reading of the proposed rule) during the Board’s Nov. 18 meeting, as outlined below. Additionally, the suggested deadline for stakeholders to provide written testimony for both Proposed Rule Part 3 - Affordability Review and Proposed Rule Part 4 - Upper Payment Limit Methodology is being extended from Friday, Sept. 30 to Thursday, Oct. 6. 

Rulemaking Status & Upcoming Hearings

Part 1: General Provisions

The Proposed Rule Part 1 - General Provisions was presented to the Board at the June 3 PDAB Meeting and was filed with the Secretary of State on June 15, 2022. On August 26, the Board voted to continue the hearing at the October 7 PDAB meeting.  

To provide written testimony, email dora_ins_pdab@state.co.us by 5 pm October 6. 

To provide verbal testimony at the October 7 meeting, sign up here

Part 3: Affordability Review

The Proposed Rule Part 3 - Affordability Reviews of Prescription Drugs was presented to the Board at the July 15 PDAB meeting. The proposed rule was published in the Colorado register on July 25, 2022. On August 26, the Board has voted to continue the hearing at the October 7 PDAB meeting. Board staff have incorporated stakeholder feedback and provided redlined versions of proposed changes to Part 3 - Affordability Reviews and Policy 04 - Affordability Reviews

To provide written testimony, email dora_ins_pdab@state.co.us by 5 pm October 6. 

To provide verbal testimony at the October 7 meeting, sign up here

Part 4: UPL Methodology

The Proposed Draft Rule Part 4 - Upper Payment Limit Methodology was presented to the Board at the August 26 PDAB meeting where the Board has voted to direct staff to file notice of the proposed rule with the Secretary of State by August 31 and to hold rulemaking hearings on October 7 and November 18.    

To provide written testimony, email dora_ins_pdab@state.co.us by 5 pm October 6. 

To provide verbal testimony at the October 7 meeting, sign up here.

Adopted Rules and Policies

Adopted Rules

Adopted Policies

Written Testimonies

Part 3 - Affordability Review

Part 4: Upper Payment Limit Methodology

Part 5: Reporting Requirements for Use of Savings

This section will be updated regularly to reflect the status of each draft proposed rule listed above. 

#FFFFFF

PDAB

The Prescription Drug Affordability Board (PDAB) is a 5 member Type-1 Board tasked with the following statutory duties:

  • Collect and evaluate data to identify drugs that may be subject to an affordability review;
  • Perform affordability reviews if certain statutory triggers occur;
  • Determine whether a prescription drug is unaffordable for Colorado consumers;
  • If a drug is found to be unaffordable, the Board may set an upper payment limit; and
  • Make policy recommendations to the General Assembly.
Board Members

The Governor appointed the following Prescription Drug Affordability Board Members on September 27, 2021:

PDAAC

The Board has appointed the 15 member Prescription Drug Affordability Advisory Council (PDAAC) to provide stakeholder input to the Board on prescription drug affordability.

All PDAAC members meet statutory requirements for composition, geographic representation, and subject matter expertise. 

To the extent possible, the Board appointed members who have experience serving underserved communities and who reflect the state’s diversity in terms of race, immigration status, income, disability, age, gender identity, and geography.

 

Council Members
  • Kim Bimestefer Executive Director of HCPF
  • Gail deVore representing health care consumers
  • Edward A. Dauer, LL.B., M.P.H. representing statewide health care advocacy organizations
  • Kimberley Jackson, DO representing consumers with chronic diseases and PDAAC Chair 
  • Maria Fenwick representing a labor union
  • Nathan Wilkes representing employers
  • Chad Friday representing carriers
  • Marc Reece representing pharmacy benefit managers
  • Thomas Tobin, MD, MBA representing health care professionals with prescribing authority
  • R. Brett McQueen, PhD representing an organization that researches prescription drugs
  • Katelin Lucariello MPH representing manufacturers of brand name drugs
  • Neal Miller representing manufacturers of generic drugs
  • Andrew Gonzales, PharmD representing pharmacists
  • Jason Atlas, RPh, MBA representing wholesalers 
#FFFFFF
Learning Series & Resources

Slides and recordings for the five part Prescription Drug Affordability Learning Series can be found below.

Learning Series 1: Data Deep Dive

View Data Deep Dive

Learning Series 2: Patient Perspectives

View Patient Perspectives

Learning Series 3: Pharmaceutical Supply Chain Panel

View Pharmaceutical Supply Chain Panel

Learning Series 4: Comparative Effectiveness & Affordability

View Comparative Effectiveness & Affordability

Learning Series 5: Prescription Drug Affordability Efforts in Colorado & Other States

View Prescription Drug Affordability Efforts in Colorado & Other States

Resources

Frequently Asked Questions

SB21-175 Text

Reducing Prescription Drug Costs in Colorado, 2nd Edition

CIVHC Top 100 Brand and Generic Commercial Payer Prescription Drugs

Contact Information & Accessibility 

Questions about the Prescription Drug Affordability Board and Advisory Council can be sent to dora_ins_pdab@state.co.us.

The Prescription Drug Affordability Program is committed to providing equal access to our meetings for all participants. If you would like to request an accommodation to attend a Board or Advisory Council meeting, please contact us at dora_ins_pdab@state.co.us with your request by the close of business at least one week in advance of a meeting.

Conflict of Interest Information

PDAB's Conflict of Interest Policy

Information required to be disclosed pursuant to §10-16-1402(3)(d) will be contained here.